FDA Inspection 1208316 — Bhavna Super Speciality Eye Care
The FDA completed an inspection of Bhavna Super Speciality Eye Care on June 15, 2023 in Surat. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 15, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Surat (India)
Additional Details
Clinical BA/BE